Fig. 2: Effect of felzartamab on molecular ABMR and TCMR scores.
a, Tracking individual patient scores for ABMR classifier (ABMRProb). The solid circles represent individual patient scores for placebo (npatients = 10) and felzartamab (npatients = 10) arms across index, week 24 and week 52 biopsies. All biopsies represent biological replicates. The solid lines illustrate the change in score from baseline to week 24 to week 52 within treatment groups. b,c, The effect of felzartamab treatment on molecular ABMR (b) and TCMR (c) activity was assessed by ART-ANOVA. The effect of treatment was assessed as the interaction term between treatment group and follow-up visit. Two-tailed tests with α = 0.05 were used for all statistical testing, and P values were corrected for multiple testing using FDR. A detailed description of statistics for b and c is included in Extended Data Table 1. The shaded regions represent density estimates by group. The solid black circles represent the median scores by treatment group at baseline, week 24 and week 52. The dashed lines illustrate the changes in median scores (Δ) from baseline to week 24 to week 52 within treatment groups. The solid colored circles represent individual patient scores. The numbers identify patients of interest. The solid colored lines illustrate the change in individual patient scores from baseline to week 24 to week 52.
